NICE issues Final Appraisal Determination for PIXUVRI (pixantrone) drug News-Medical.net ... showing PIXUVRI's cost effectiveness and recommended the treatment as an option for certain people with histologically confirmed aggressive B-cell NHL who have previously received rituximab and are receiving PIXUVRI as a third- or fourth-line ... PIXUVRI® (pixantrone) Receives Positive Final Appraisal Determination from ... |
